A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France

References

• FerlayJSteliarova-FoucherELortet-TieulentJCancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012Eur J Cancer20134961374140323485231
   PubMed Web of Science ®Google Scholar
• TomasiniPBerlesiFMascauxGerillierLPemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomesTher Adv Med Oncol20168319820827239238
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNon–Small Cell Lung Cancer Version 52017 Available from: www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdfAccessed April 17, 2017
   Google Scholar
• NovelloSBarlesiFCalifanoRMetastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201627Suppl 5v1v2727664245
   PubMed Web of Science ®Google Scholar
• MastersGATeminSAzzoliCGSystemic therapy for stage IV non-small-cell lung cancer: American Society of Oncology clinical practice guidelines updateJ Clin Oncol201533303488351526324367
   PubMed Web of Science ®Google Scholar
• Haute Autorité de SantéAlimta (pemetrexed), antimetabolite2016 Avalable from: https://www.has-sante.fr/portail/jcms/c_2628546/fr/alimta-mesotheliomeAccessed May 21, 2017
   Google Scholar
• Alimta 100/500 mg [summary of product characteristics]2009 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000564/WC500025611.pdfAccessed April 21, 2017
   Google Scholar
• ScagliottiGVParikhPvon PawelJPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol200826213543355118506025
   PubMed Web of Science ®Google Scholar
• Paz-AresLde MarinisFDediuMMaintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trialLancet Oncol201213324725522341744
   PubMed Web of Science ®Google Scholar
• CiuleanuTBrodowiczTZielinskiCMaintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyLancet200937496991432144019767093
   PubMed Web of Science ®Google Scholar
• HannaNShephardFAFossellaFVRandomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyJ Clin Oncol20042291589159715117980
   PubMed Web of Science ®Google Scholar
• CappuzzoFCiuleanuTStelmakhLErlotinib as maintenance treatment in advanced, non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet Oncol201011652152920493771
   PubMed Web of Science ®Google Scholar
• BrodowiczTKrzakowskiMZwitterMCisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trialLung Cancer200652215516316569462
   PubMed Web of Science ®Google Scholar
• BarlesiFScherpereelARittmeyerARandomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089)J Clin Oncol201331243004301123835708
   PubMed Web of Science ®Google Scholar
• Lopez-ChavezAYoungTFagesSBevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 study: results of an exploratory analysisJ Thorac Oncol20127111707171223059774
   PubMed Web of Science ®Google Scholar
• PérolMChouaidCPérolDRandomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol201230283516352422949150
   PubMed Web of Science ®Google Scholar
• BrydenPKumarGWinfreeKBA cost-effectiveness analysis of cisplatin plus pemetrexed doublet induction treatment followed by pemetrexed maintenance compared with bevacizumab plus cisplatin plus gemcitabine triplet induction treatment followed by bevacizumab maintenance for non-squamous NSCLC in SwedenPoster presented at: ISPOR 16th Annual European CongressNovember 2–6, 2013Dublin, Ireland
   Google Scholar
• KumarGWoodsBHessLMCost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.SLung Cancer201589329430026122345
   PubMed Web of Science ®Google Scholar
• Institut National du Cancer [homepage on the Internet] Available from: http://www.e-cancer.frAccessed June 14, 2016
   Google Scholar
• European Medicines AgencySummary of opinion (post authorisation): Tarceva (erlotinib)2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000618/WC500199001.pdfAccessed June 14, 2016
   Google Scholar
• NafeesBStaffordMGavrielSBhallaSWatkinsJHealth state utilities for non-small cell lung cancerHealth Qual Life Outcomes200868418939982
   PubMed Web of Science ®Google Scholar
• SeséLDidierMRousseau-BussacGCrequitPMasanesMJChouaidCChemotherapy at the end of life for patients with lung cancer: a practice analysisRev Mal Respir2015323256261 French25847203
   PubMed Web of Science ®Google Scholar
• Haute Autorité de SantéChoices in methods for economic evaluation2012 Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdfAccessed June 14, 2016
   Google Scholar
• WoodsBSHawkinsNScottDANetwork meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorialBMC Med Res Methodol2010105420537177
   PubMed Web of Science ®Google Scholar
• NihoSKunitohHNokiharaHRandomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancerLung Cancer201276336236722244743
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPOverall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Ann Oncol20102191804180920150572
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• SandlerAYiJDahlbergSTreatment outcomes by tumor histology in Eastern Cooperative Group study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancerJ Thorac Oncol2010591416142320686429
   PubMed Web of Science ®Google Scholar
• SpiegelhalterDJBestNGCarlinBPvan der LindeABayesian measures of model complexity and fitJ R Stat Soc Series B Stat Methodol2002644583639
   Web of Science ®Google Scholar
• AkaikeHAkaike’s information criterion2014 Available from: http://link.springer.com/referenceworkentry/10.1007/978-3-642-04898-2_110Accessed May 22, 2017
   Google Scholar
• CollettDModelling Survival Data in Medical ResearchBoca Raton (FL)Chapman & Hall2003
   Google Scholar
• GridelliCde MarinisFPujolJLSafety, resource use, and quality of life in PARAMOUNT: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerJ Thorac Oncol20127111713172123059776
   PubMed Web of Science ®Google Scholar
• ChevalierJde PouvourvilleGValuing EQ-5D using time trade-off in FranceEur J Health Econ2013141576621935715
   PubMed Web of Science ®Google Scholar
• L’Assurance-Maladie. Base des médicaments et informations tarifaires. 2015. [Health Insurance. Drug base and pricing information] Available from: http://www.codage.ext.cnamts.fr/codif/bdm_it/Accessed June 14, 2016 French
   Google Scholar
• Agence Technique de l’Information sur l’Hospitalisation. Tarifs MCO et HAD. 2015. [Technical Agency of Information on Hospitalization. MCO and HAD tariffs] Available from: http://www.atih.sante.fr/tarifs-mco-et-hadAccessed June 14, 2016 French
   Google Scholar
• BanzKBischoffHBrunnerMComparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and SpainLung Cancer201174352953421592611
   PubMed Web of Science ®Google Scholar
• MickischGGoreMEscudierBProcopioGWalzerSNuijtenMCosts of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinibBr J Cancer20101021808619920817
   PubMed Web of Science ®Google Scholar
• Durand-ZaleskiLVainchtockABogillotOUse of an administrative database to estimate the economic burden of febrile neutropeniaJ Econ Med200725269280 French
   Google Scholar
• Paz-AresLGde MarinisFDediuMPARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerJ Clin Oncol201331232895290223835707
   PubMed Web of Science ®Google Scholar
• FenwickEClaxtonKSculpherMRepresenting uncertainty: the role of cost-effectiveness acceptability curvesHealth Econ200110877978711747057
   PubMed Web of Science ®Google Scholar
• BartonGRBriggsAHFenwickEAOptimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI)Value Health200811588689718489513
   PubMed Web of Science ®Google Scholar
• BongersMLCoupéVMJansmaEPSmitEFUyl-de GrootCACost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic reviewPharmacoeconomics2012301173422201521
   PubMed Web of Science ®Google Scholar
• ChouaïdCCrequitPBorfetIVergnenegreAEconomic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic reviewClinicoecon Outcomes Res2014791525548525
   PubMedGoogle Scholar
• BrownTPilkingtonGBagustAClinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluationHealth Technol Assess201317311278
   Web of Science ®Google Scholar
• GreenhalghJMcLeodCBagustAPemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancerHealth Technol Assess201014Suppl 2333921047489
   PubMed Web of Science ®Google Scholar
• CaroJJBriggsAHSiebertUKuntzKMModeling good research practices – overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1Value Health201215679680322999128
   PubMed Web of Science ®Google Scholar
• RamseySWillkeRBriggsAGood research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force reportValue Health20058552153316176491
   PubMed Web of Science ®Google Scholar